265 related articles for article (PubMed ID: 36845711)
1. PTCL, NOS: An update on classification, risk-stratification, and treatment.
Weiss J; Reneau J; Wilcox RA
Front Oncol; 2023; 13():1101441. PubMed ID: 36845711
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
[TBL] [Abstract][Full Text] [Related]
3. Molecular understanding of peripheral T-cell lymphomas, not otherwise specified (PTCL, NOS): A complex disease category.
Sakata-Yanagimoto M; Fukumoto K; Karube K; Chiba S
J Clin Exp Hematop; 2021 Jun; 61(2):61-70. PubMed ID: 33716242
[TBL] [Abstract][Full Text] [Related]
4. Frequency, distribution, and immunomorphologic characteristics of peripheral T-cell lymphoma, not otherwise specified in a tertiary care center in Southern India.
Lakshmanan A; Sikri D; Patil S; Kurian A; Annapurneswari S; Nair S
Indian J Pathol Microbiol; 2018; 61(2):204-208. PubMed ID: 29676358
[TBL] [Abstract][Full Text] [Related]
5. Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS.
Cutucache CE; Herek TA
Front Oncol; 2016; 6():206. PubMed ID: 27725924
[TBL] [Abstract][Full Text] [Related]
6. Distinct and overlapping features of nodal peripheral T-cell lymphomas exhibiting a follicular helper T-cell phenotype: a multicenter study emphasizing the clinicopathological significance of follicular helper T-cell marker expression.
Paik JH; Koh J; Han B; Kim S; Lee KR; Lee S; Lee JO; Kim TM; Kim WY; Jeon YK
Hum Pathol; 2023 Jan; 131():47-60. PubMed ID: 36495942
[TBL] [Abstract][Full Text] [Related]
7. Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs).
Moskowitz AJ; Stuver RN; Horwitz SM
Blood; 2024 Feb; ():. PubMed ID: 38306597
[TBL] [Abstract][Full Text] [Related]
8. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
Armitage JO
Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas.
Yoon SE; Cho J; Kim YJ; Ko YH; Park WY; Kim SJ; Kim WS
Exp Hematol Oncol; 2021 May; 10(1):33. PubMed ID: 33990228
[TBL] [Abstract][Full Text] [Related]
10. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.
Ludvigsen M; Bjerregård Pedersen M; Lystlund Lauridsen K; Svenstrup Poulsen T; Hamilton-Dutoit SJ; Besenbacher S; Bendix K; Møller MB; Nørgaard P; d'Amore F; Honoré B
Blood Adv; 2018 Oct; 2(19):2533-2542. PubMed ID: 30291111
[TBL] [Abstract][Full Text] [Related]
11. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS).
Oluwasanjo A; Kartan S; Johnson W; Alpdogan O; Gru A; Mishra A; Haverkos BM; Gong J; Porcu P
Cancer Treat Res; 2019; 176():83-98. PubMed ID: 30596214
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
Piccaluga PP; Fuligni F; De Leo A; Bertuzzi C; Rossi M; Bacci F; Sabattini E; Agostinelli C; Gazzola A; Laginestra MA; Mannu C; Sapienza MR; Hartmann S; Hansmann ML; Piva R; Iqbal J; Chan JC; Weisenburger D; Vose JM; Bellei M; Federico M; Inghirami G; Zinzani PL; Pileri SA
J Clin Oncol; 2013 Aug; 31(24):3019-25. PubMed ID: 23857971
[TBL] [Abstract][Full Text] [Related]
13. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Aberrations and Targets in Peripheral T-Cell Lymphoma.
Atallah-Yunes SA; Robertson MJ; Davé UP
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):659-665. PubMed ID: 35577752
[TBL] [Abstract][Full Text] [Related]
15. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
Sugio T; Miyawaki K; Kato K; Sasaki K; Yamada K; Iqbal J; Miyamoto T; Ohshima K; Maeda T; Miyoshi H; Akashi K
Blood Adv; 2018 Sep; 2(17):2242-2252. PubMed ID: 30194138
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with Indolent Behavior.
Guarnera L; Boldrini V; Pasqualone G; Cimino C; Meddi E; Laureana R; Trivigno D; Del Poeta G; Mauriello A; Anemona L; Postorino M; Cantonetti M
Mediterr J Hematol Infect Dis; 2022; 14(1):e2022006. PubMed ID: 35070213
[TBL] [Abstract][Full Text] [Related]
17. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
18. A lower ALC/AMC ratio is associated with poor prognosis of peripheral T-cell lymphoma-not otherwise specified.
Li Q; Gao S; Ma J; Liu S; Yue Y; Chen L; Li H; Wang X; Li D; Cao Z; Zhao Z; Wang X; Yu Y; Zhang Y; Wang Y
Leuk Res; 2018 Oct; 73():5-11. PubMed ID: 30172956
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis in PTCL-NOS with CADM1 expression.
Kato T; Miyoshi H; Kobayashi S; Yoshida N; Imaizumi Y; Seto M; Uchimaru K; Miyazaki Y; Ohshima K
Virchows Arch; 2017 Nov; 471(5):659-666. PubMed ID: 28940014
[TBL] [Abstract][Full Text] [Related]
20. Mutation analysis links angioimmunoblastic T-cell lymphoma to clonal hematopoiesis and smoking.
Cheng S; Zhang W; Inghirami G; Tam W
Elife; 2021 Sep; 10():. PubMed ID: 34581268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
